ストックスクリーナーアプリを入手
25.82
2.54%
0.64
前日終値:
$25.18
開ける：
$25.39
24時間の取引高:
311.01K
Relative Volume:
0.40
時価総額：
$1.39B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.81%
1か月 パフォーマンス:
+24.98%
6か月 パフォーマンス:
+52.06%
1年 パフォーマンス:
+272.58%
1日の値動き範囲:
$24.18
$26.86
1週間の範囲:
$24.18
$26.86
52週間の値動き範囲:
$6.11
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
25.82 | 1.35B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
ZBIO SEC FilingsZenas BioPharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 18.8% in February - MarketBeat
What is the target price for Zenas BioPharma Inc stockPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory - Insider Monkey
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 54.59% Potential Upside Awaits Investors - DirectorsTalk Interviews
Short Covering: Will Zenas BioPharma Inc outperform during market rallies - baoquankhu1.vn
A Look At Zenas BioPharma (ZBIO) Valuation As Obexelimab Shows Strong ACTRIMS 2026 Efficacy Data - Sahm
Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Encouraging phase II trial data supported Zenas BioPharma (ZBIO) in Q4 - MSN
Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 - Finviz
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4 - Insider Monkey
Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial SuccessAnd What's Next - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpHere's Why - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Street Watch: Is Zenas BioPharma Inc a good ESG investment2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit - MarketBeat
Fundamentals Check: Is Zenas BioPharma Inc stock a good pick for beginnersJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What Wall Street predicts for Zenas BioPharma Inc. stock priceJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - mfd.ru
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $390,145.00 in Stock - MarketBeat
Hongbo Lu Buys 25,985 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock - MarketBeat
Zenas BioPharma Adopts Amended Short-Term Incentive Plan - TipRanks
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 56% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
Will Zenas BioPharma Inc. outperform during market ralliesWeekly Trade Analysis & Low Risk Investment Opportunities - mfd.ru
Can Zenas BioPharma Inc. be the next market leaderTreasury Yields & Community Consensus Stock Picks - mfd.ru
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions - Investing.com Nigeria
Zenas BioPharma approves 2026 inducement plan - MSN
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Australia
Zenas BioPharma Meets Key Goal In Phase 2 MoonStone Trial Of Obexelimab In R/Multiple Sclerosis - RTTNews
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewswire
Zenas Biopharma Announces Late-Breaking Platform Presentation Of Results From Phase 2 Moonstone Trial Of Obexelimab In Relapsing Multiple Sclerosis At Actrims Forum 2026 - TradingView
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Zenas BioPharma (ZBIO) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
A Big Boss Bet on Zenas BioPharma’s Future - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys 57,000 Shares - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Shares Up 8.9%Here's Why - MarketBeat
Chipmakers Recap: What is the target price for Zenas BioPharma Inc stockJuly 2025 Catalysts & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO - ChartMill
Zenas Biopharma Inc (ZBIO) 財務データ
Zenas Biopharma Inc (ZBIO) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Zenas Biopharma Inc (ZBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 02 '26 |
Buy |
17.96 |
57,000 |
1,023,720 |
423,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 07 '26 |
Buy |
16.38 |
50,000 |
819,000 |
316,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 08 '26 |
Buy |
16.30 |
30,000 |
489,000 |
346,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Jan 09 '26 |
Buy |
16.55 |
20,000 |
331,000 |
366,155 |
| Nunn Jason Raleigh | Director |
Oct 09 '25 |
Buy |
19.00 |
63,158 |
1,200,002 |
1,173,395 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Oct 09 '25 |
Buy |
19.00 |
126,315 |
2,399,985 |
1,917,895 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
19.00 |
105,265 |
2,000,035 |
1,832,669 |
| ENRIGHT PATRICK G | Director |
Oct 09 '25 |
Buy |
20.85 |
11,990 |
249,992 |
11,990 |
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):